logo

News

Osteoarthritis affects 17% of the Spanish population and costs more than 4,700 million every year

Bioibérica Farma, the only Spanish company specializing in the treatment of osteoarthritis, launches an osteoarthritis awareness campaign.

According to the World Health Organization (WHO), osteoarthritis is the fourth most common cause of loss of Quality Adjusted Life Years.

Biomarkers could be key to predict osteoarthritis progression

Dr. Cristóbal Orellana, Associate Physician at the Service of Rheumatology of the Parc Taulí Hospital (Sabadell, Barcelona) commented that biomarkers extracted from type II collagen, a type of collagen that can be found only in the cartilage, holds great promise for diagnosing osteoarthritis, and for monitoring its treatment.



The World Congress on Osteoarthritis (OARSI)

Genetics, key to predict the progression of osteoarthritis

Bioibérica leads a research project aiming at predicting Osteoarthritis development from a saliva sample

Francisco J. Blanco García, rheumatologist of the A Coruña University Hospital Complex will present the “Arthrosischip” Project, which aims to predict the development of osteoarthritis. Bioibérica is the only Spanish pharmaceutical company that will be present at OARSI 2011

They will sponsor two symposiums, one on personalized medicine, and another on the treatment of chronic osteoarthritis

The city of Barcelona, in collaboration with Bioibérica, will host OARSI2012.


Presented a clinical trial that confirmed for the first time, using quantitative Magnetic Resonance Imaging, the efficacy of chondroitin sulphate to stop the progression of osteoarthritis

BIOIBERICA has been present at the EULAR Congress 2011, the most important European event on rheumatic diseases. This year' edition has been held in London, UK.

Professor Jean-Pierre Pelletier from Montreal, Canada, presented the results of a clinical trial that confirm the disease-modifying effects of chondroitin sulphate. These results have also been presented in an article published in the June issue of Annals of the Rheumatic Diseases. Spanish rheumatologist Francisco J. Blanco, from the Corunna hospital, confirmed the efficacy of the combination of chondroitin sulphate and glucosamine to combat osteoarthritis.

Dr. Virginia Byers Kraus from Durham, USA, determined that osteoarthritis has an important inflammatory aspect, thus redefining our concepts about that disease

New chip could predict development of knee osteoarthritis from DNA analysis

The Arthrosischip is a new diagnostic tool. Based upon the genetic information of every individual, it could predict the future development of knee osteoarthritis

Rheumatologist Dr. Francisco Blanco Garcia presented in the XXXVII National Congress of the Spanish Society of Rheumatology (SER 2011), held in Malaga, the research project that is working on the development of that tool. Thirty-two research centres from all over Spain are participating in this project

The disease modifying effect of chondroitin sulphate in patients with knee osteoarthritis has been confirmed by MRI

A clinical trial by Prof. Jean-Pierre Pelletier has been published in Annals of the Rheumatic Diseases this week


Any doubt?
Contact us and we will write
you as soon as posible.

Contact